Personalis (NASDAQ:PSNL) Price Target Raised to $9.00

Personalis (NASDAQ:PSNL) had its price target hoisted by equities researchers at Lake Street Capital from $7.00 to $9.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Lake Street Capital’s target price points to a potential upside of 60.71% from the company’s current price.

PSNL has been the subject of several other reports. Needham & Company LLC reissued a “buy” rating and set a $7.25 target price on shares of Personalis in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Personalis in a report on Wednesday.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $5.60 on Wednesday. Personalis has a 1 year low of $1.12 and a 1 year high of $7.20. The firm has a market cap of $395.63 million, a P/E ratio of -3.33 and a beta of 1.75. The stock has a fifty day moving average price of $4.70 and a two-hundred day moving average price of $4.33.

Personalis (NASDAQ:PSNL) last announced its earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The firm had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. During the same period in the prior year, the business earned ($0.51) EPS. On average, research analysts predict that Personalis will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of Personalis

Several hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC grew its holdings in shares of Personalis by 6.7% during the 2nd quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock valued at $1,237,000 after acquiring an additional 66,128 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in Personalis by 42.5% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after purchasing an additional 4,504 shares in the last quarter. nVerses Capital LLC acquired a new position in Personalis in the 3rd quarter worth about $40,000. International Assets Investment Management LLC increased its position in Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock worth $113,000 after purchasing an additional 17,082 shares during the last quarter. Finally, Semanteon Capital Management LP purchased a new stake in shares of Personalis during the 3rd quarter worth about $375,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.